scholarly journals Artificial intelligence in arthroplasty

Arthroplasty ◽  
2021 ◽  
Vol 3 (1) ◽  
Author(s):  
Glen Purnomo ◽  
Seng-Jin Yeo ◽  
Ming Han Lincoln Liow
Keyword(s):  
Artificial Intelligence ◽  
Clinical Decision Making ◽  
Recent Literature ◽  
Improve Patient Care ◽  
Clinical Decision ◽  
Patient Specific ◽  
Allocation Decision ◽  
Medical Specialties ◽  
Future Direction ◽  
Improve Patient

AbstractArtificial intelligence (AI) is altering the world of medicine. Given the rapid advances in technology, computers are now able to learn and improve, imitating humanoid cognitive function. AI applications currently exist in various medical specialties, some of which are already in clinical use. This review presents the potential uses and limitations of AI in arthroplasty to provide a better understanding of the existing technology and future direction of this field.Recent literature demonstrates that the utilization of AI in the field of arthroplasty has the potential to improve patient care through better diagnosis, screening, planning, monitoring, and prediction. The implementation of AI technology will enable arthroplasty surgeons to provide patient-specific management in clinical decision making, preoperative health optimization, resource allocation, decision support, and early intervention. While this technology presents a variety of exciting opportunities, it also has several limitations and challenges that need to be overcome to ensure its safety and effectiveness.

scholarly journals Artificial Intelligence, Heuristic Biases, and the Optimization of Health Outcomes: Cautionary Optimism

2021 ◽  
Vol 10 (22) ◽  
pp. 5284
Author(s):  
Michael Feehan ◽  
Leah A. Owen ◽  
Ian M. McKinnon ◽  
Margaret M. DeAngelis
Keyword(s):  
Artificial Intelligence ◽  
Health Outcomes ◽  
Clinical Decision Making ◽  
Clinical Care ◽  
Clinical Decision ◽  
Health Inequity ◽  
Great Promise ◽  
Patient Health ◽  
Improve Patient ◽  
Regulatory Landscapes

The use of artificial intelligence (AI) and machine learning (ML) in clinical care offers great promise to improve patient health outcomes and reduce health inequity across patient populations. However, inherent biases in these applications, and the subsequent potential risk of harm can limit current use. Multi-modal workflows designed to minimize these limitations in the development, implementation, and evaluation of ML systems in real-world settings are needed to improve efficacy while reducing bias and the risk of potential harms. Comprehensive consideration of rapidly evolving AI technologies and the inherent risks of bias, the expanding volume and nature of data sources, and the evolving regulatory landscapes, can contribute meaningfully to the development of AI-enhanced clinical decision making and the reduction in health inequity.

scholarly journals Decision Models and Technology Can Help Psychiatry Develop Biomarkers

2021 ◽  
Vol 12 ◽  
Author(s):  
Daniel S. Barron ◽  
Justin T. Baker ◽  
Kristin S. Budde ◽  
Danilo Bzdok ◽  
Simon B. Eickhoff ◽  
...  
Keyword(s):  
Clinical Data ◽  
Decision Model ◽  
Empirical Evaluation ◽  
Improve Patient Care ◽  
Clinical Decision ◽  
Decision Models ◽  
Phenotypic Data ◽  
Medical Specialties ◽  
Fundamental Reason ◽  
Improve Patient

Why is psychiatry unable to define clinically useful biomarkers? We explore this question from the vantage of data and decision science and consider biomarkers as a form of phenotypic data that resolves a well-defined clinical decision. We introduce a framework that systematizes different forms of phenotypic data and further introduce the concept of decision model to describe the strategies a clinician uses to seek out, combine, and act on clinical data. Though many medical specialties rely on quantitative clinical data and operationalized decision models, we observe that, in psychiatry, clinical data are gathered and used in idiosyncratic decision models that exist solely in the clinician's mind and therefore are outside empirical evaluation. This, we argue, is a fundamental reason why psychiatry is unable to define clinically useful biomarkers: because psychiatry does not currently quantify clinical data, decision models cannot be operationalized and, in the absence of an operationalized decision model, it is impossible to define how a biomarker might be of use. Here, psychiatry might benefit from digital technologies that have recently emerged specifically to quantify clinically relevant facets of human behavior. We propose that digital tools might help psychiatry in two ways: first, by quantifying data already present in the standard clinical interaction and by allowing decision models to be operationalized and evaluated; second, by testing whether new forms of data might have value within an operationalized decision model. We reference successes from other medical specialties to illustrate how quantitative data and operationalized decision models improve patient care.

scholarly journals Research methods: Clinical studies based on routine laboratory tests

2018 ◽  
Vol 6 (23) ◽  
pp. 33-39
Author(s):  
Shengping Yang ◽  
Menfil Orellana-Barrios ◽  
Kenneth Nugent
Keyword(s):  
Laboratory Tests ◽  
Clinical Decision Making ◽  
Diagnostic Testing ◽  
Improve Patient Care ◽  
Clinical Decision ◽  
Routine Laboratory ◽  
Coronary Syndrome ◽  
The Mean ◽  
Treatment Responses ◽  
Improve Patient

Clinical research using routine laboratory tests can provide important opportunities to investigators, especially those with limited resources, and can improve patient care, especially if the result improves clinical decision making without the use of more sophisticated or expensive tests. Laboratory analysis of biological parameters can be used for screening, diagnostic testing, predicting prognosis, and measuring treatment responses. Often the same parameter can be used for several purposes, depending on the clinical scenario and the patient population. For example, several studies have suggested the mean platelet volume (MPV) is different in patients with acute coronary syndrome compared to patients with coronary disease but no acute syndrome. Given this information it might seem relatively easy to start studies using this laboratory test. However, multiple questions need to be considered before starting any research using MPV measurements. We will discuss some of these considerations in this review article. This approach applies to most research projects based on laboratory tests.

scholarly journals How will artificial intelligence and bioinformatics change our understanding of IgA in the next decade?

2021 ◽  
Author(s):  
Roman David Bülow ◽  
Daniel Dimitrov ◽  
Peter Boor ◽  
Julio Saez-Rodriguez
Keyword(s):  
Artificial Intelligence ◽  
Multidisciplinary Approach ◽  
Immunoglobulin A ◽  
Improve Patient Care ◽  
Integrated Analysis ◽  
Clinical Expertise ◽  
End Stage ◽  
The Complement System ◽  
Improve Patient ◽  
Generation Sequencing

AbstractIgA nephropathy (IgAN) is the most common glomerulonephritis. It is characterized by the deposition of immune complexes containing immunoglobulin A (IgA) in the kidney’s glomeruli, triggering an inflammatory process. In many patients, the disease has a progressive course, eventually leading to end-stage kidney disease. The current understanding of IgAN’s pathophysiology is incomplete, with the involvement of several potential players, including the mucosal immune system, the complement system, and the microbiome. Dissecting this complex pathophysiology requires an integrated analysis across molecular, cellular, and organ scales. Such data can be obtained by employing emerging technologies, including single-cell sequencing, next-generation sequencing, proteomics, and complex imaging approaches. These techniques generate complex “big data,” requiring advanced computational methods for their analyses and interpretation. Here, we introduce such methods, focusing on the broad areas of bioinformatics and artificial intelligence and discuss how they can advance our understanding of IgAN and ultimately improve patient care. The close integration of advanced experimental and computational technologies with medical and clinical expertise is essential to improve our understanding of human diseases. We argue that IgAN is a paradigmatic disease to demonstrate the value of such a multidisciplinary approach.

Sports Medicine and Artificial Intelligence: A Primer

2021 ◽  
pp. 036354652110086
Author(s):  
Prem N. Ramkumar ◽  
Bryan C. Luu ◽  
Heather S. Haeberle ◽  
Jaret M. Karnuta ◽  
Benedict U. Nwachukwu ◽  
...  
Keyword(s):  
Artificial Intelligence ◽  
Sports Medicine ◽  
Injury Risk ◽  
Industrial Revolution ◽  
Improve Patient Care ◽  
Great Promise ◽  
Patient Reported ◽  
Athlete Injury ◽  
Improve Patient ◽  
Applications Of Ai

Artificial intelligence (AI) represents the fourth industrial revolution and the next frontier in medicine poised to transform the field of orthopaedics and sports medicine, though widespread understanding of the fundamental principles and adoption of applications remain nascent. Recent research efforts into implementation of AI in the field of orthopaedic surgery and sports medicine have demonstrated great promise in predicting athlete injury risk, interpreting advanced imaging, evaluating patient-reported outcomes, reporting value-based metrics, and augmenting the patient experience. Not unlike the recent emphasis thrust upon physicians to understand the business of medicine, the future practice of sports medicine specialists will require a fundamental working knowledge of the strengths, limitations, and applications of AI-based tools. With appreciation, caution, and experience applying AI to sports medicine, the potential to automate tasks and improve data-driven insights may be realized to fundamentally improve patient care. In this Current Concepts review, we discuss the definitions, strengths, limitations, and applications of AI from the current literature as it relates to orthopaedic sports medicine.

scholarly journals Clinician checklist for assessing suitability of machine learning applications in healthcare

2021 ◽  
Vol 28 (1) ◽  
pp. e100251
Author(s):  
Ian Scott ◽  
Stacey Carter ◽  
Enrico Coiera
Keyword(s):  
Machine Learning ◽  
Large Scale ◽  
Clinical Decision Making ◽  
Improve Patient Care ◽  
Clinical Decision ◽  
Routine Care ◽  
Machine Learning Algorithms ◽  
Clinical Settings ◽  
Machine Learning Applications ◽  
Key Issues

Machine learning algorithms are being used to screen and diagnose disease, prognosticate and predict therapeutic responses. Hundreds of new algorithms are being developed, but whether they improve clinical decision making and patient outcomes remains uncertain. If clinicians are to use algorithms, they need to be reassured that key issues relating to their validity, utility, feasibility, safety and ethical use have been addressed. We propose a checklist of 10 questions that clinicians can ask of those advocating for the use of a particular algorithm, but which do not expect clinicians, as non-experts, to demonstrate mastery over what can be highly complex statistical and computational concepts. The questions are: (1) What is the purpose and context of the algorithm? (2) How good were the data used to train the algorithm? (3) Were there sufficient data to train the algorithm? (4) How well does the algorithm perform? (5) Is the algorithm transferable to new clinical settings? (6) Are the outputs of the algorithm clinically intelligible? (7) How will this algorithm fit into and complement current workflows? (8) Has use of the algorithm been shown to improve patient care and outcomes? (9) Could the algorithm cause patient harm? and (10) Does use of the algorithm raise ethical, legal or social concerns? We provide examples where an algorithm may raise concerns and apply the checklist to a recent review of diagnostic imaging applications. This checklist aims to assist clinicians in assessing algorithm readiness for routine care and identify situations where further refinement and evaluation is required prior to large-scale use.

scholarly journals Ondansetron use is associated with lower COVID-19 mortality in a Real-World Data network-based analysis

2021 ◽  
Author(s):  
Gregory M Miller ◽  
Austin J Ellis ◽  
Rangaprasad Sarangarajan ◽  
Amay Parikh ◽  
Leonardo O Rodrigues ◽  
...  
Keyword(s):  
Artificial Intelligence ◽  
Real World ◽  
Clinical Decision Making ◽  
Clinical Decision ◽  
Long Term Effects ◽  
Real World Data ◽  
World Data ◽  
Antiemetic Agent ◽  
Future Loss ◽  
Selection Operator

Objective: The COVID-19 pandemic generated a massive amount of clinical data, which potentially holds yet undiscovered answers related to COVID-19 morbidity, mortality, long term effects, and therapeutic solutions. The objective of this study was to generate insights on COVID-19 mortality-associated factors and identify potential new therapeutic options for COVID-19 patients by employing artificial intelligence analytics on real-world data. Materials and Methods: A Bayesian statistics-based artificial intelligence data analytics tool (bAIcis®) within Interrogative Biology® platform was used for network learning, inference causality and hypothesis generation to analyze 16,277 PCR positive patients from a database of 279,281 inpatients and outpatients tested for SARS-CoV-2 infection by antigen, antibody, or PCR methods during the first pandemic year in Central Florida. This approach generated causal networks that enabled unbiased identification of significant predictors of mortality for specific COVID-19 patient populations. These findings were validated by logistic regression, regression by least absolute shrinkage and selection operator, and bootstrapping. Results: We found that in the SARS-CoV-2 PCR positive patient cohort, early use of the antiemetic agent ondansetron was associated with increased survival in mechanically ventilated patients. Conclusions: The results demonstrate how real world COVID-19 focused data analysis using artificial intelligence can generate valid insights that could possibly support clinical decision-making and minimize the future loss of lives and resources.

Sign in / Sign up

Export Citation Format

Share Document